Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment
- PMID: 22784013
- PMCID: PMC3473112
- DOI: 10.1111/j.1369-1600.2012.00471.x
Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment
Abstract
To evaluate the role of the functional Asn40Asp polymorphism in the mu-opioid receptor gene on drinking behavior and naltrexone's ability to attenuate drinking, we used a daily diary method in a 12-week, randomized clinical trial of naltrexone to reduce drinking. Participants (n = 158 problem drinkers) were assigned to receive either daily or targeted naltrexone 50 mg (n = 81) or matching placebo (n = 77). Patients reported by telephone each evening their current desire to drink and their drinking during the previous night and during the reporting day. We examined genotype, medication, desire to drink and their interactions as predictors of nighttime drinks consumed, controlling for drinking earlier in the day. Asp40 carriers showed a stronger positive association between evening desire (deviations from their mean levels) and later night drinking levels than Asn40 homozygotes (P = 0.019). The desire × genotype × medication condition interaction was also significant (P = 0.009), with a significant desire × genotype interaction for the placebo group (P = 0.001) but not for the naltrexone group (P = 0.74). In summary, when the evening level of desire to drink was relatively high, Asp40 allele carriers were at greater risk than Asn40 homozygotes to drink more, which was attenuated by naltrexone. Although average measures across the study were not informative, daily reports helped to demonstrate the moderating effects of genetic variation on the relation between desire to drink and alcohol consumption and the effects of naltrexone on that phenotype.
© 2012 The Authors, Addiction Biology © 2012 Society for the Study of Addiction.
Figures
Similar articles
-
An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.Arch Gen Psychiatry. 2008 Feb;65(2):135-44. doi: 10.1001/archpsyc.65.2.135. Arch Gen Psychiatry. 2008. PMID: 18250251 Free PMC article. Clinical Trial.
-
Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.Alcohol Clin Exp Res. 2012 Nov;36(11):2000-7. doi: 10.1111/j.1530-0277.2012.01807.x. Epub 2012 May 2. Alcohol Clin Exp Res. 2012. PMID: 22551036 Free PMC article. Clinical Trial.
-
Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.Addiction. 2020 Aug;115(8):1426-1437. doi: 10.1111/add.14975. Epub 2020 Feb 11. Addiction. 2020. PMID: 31961981 Free PMC article.
-
Genetic moderators of naltrexone's effects on alcohol cue reactivity.Alcohol Clin Exp Res. 2006 Aug;30(8):1288-96. doi: 10.1111/j.1530-0277.2006.00156.x. Alcohol Clin Exp Res. 2006. PMID: 16899031 Clinical Trial.
-
The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.J Clin Psychopharmacol. 2006 Dec;26(6):610-25. doi: 10.1097/01.jcp.0000245566.52401.20. J Clin Psychopharmacol. 2006. PMID: 17110818 Review.
Cited by
-
The pharmacogenetics of alcohol use disorder.Alcohol Clin Exp Res. 2015 Mar;39(3):391-402. doi: 10.1111/acer.12643. Epub 2015 Feb 19. Alcohol Clin Exp Res. 2015. PMID: 25703505 Free PMC article. Review.
-
Medication-enhanced behavior therapy for alcohol use disorder: Naltrexone, Alcoholics Anonymous Facilitation, and OPRM1 genetic variation.J Subst Abuse Treat. 2019 Sep;104:7-14. doi: 10.1016/j.jsat.2019.05.004. Epub 2019 May 4. J Subst Abuse Treat. 2019. PMID: 31370987 Free PMC article.
-
Bi-directional Acceleration of Alcohol Use and Opioid Use Disorder.J Drug Alcohol Res. 2019 Oct 18;2019:236084. J Drug Alcohol Res. 2019. PMID: 32440365 Free PMC article.
-
Targeted opioid receptor antagonists in the treatment of alcohol use disorders.CNS Drugs. 2013 Oct;27(10):777-87. doi: 10.1007/s40263-013-0096-4. CNS Drugs. 2013. PMID: 23881605 Free PMC article. Review.
-
5-HTTLPR genotype and daily negative mood moderate the effects of sertraline on drinking intensity.Addict Biol. 2013 Nov;18(6):1024-31. doi: 10.1111/adb.12007. Epub 2012 Nov 12. Addict Biol. 2013. PMID: 23145795 Free PMC article. Clinical Trial.
References
-
- Anton RF, Oroszi G, O’Malley S, Couper D, Swift R, Pettinati H, Goldman D. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008;65:135–144. - PMC - PubMed
-
- Arias A, Feinn R, Kranzler HR. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 2006;83:262–268. - PubMed
-
- Armeli S, Tennen H, Affleck G, Kranzler HR. Does affect mediate the association between daily events and alcohol use? J Stud Alcohol. 2000;61:862–871. - PubMed
-
- Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, Goldman D. Mu-opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry. 1997;2:490–494. - PubMed
-
- Coller JK, Cahill S, Edmonds C, Farquharson AL, Longo M, Minniti R, Sullivan T, Somogyi AA, White JM. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenet Genomics. 2011;21:902–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials